Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/132133
Title: TREATMENT AND MODELING OF EPSTEIN-BARR VIRUS POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Authors: TAN WEI JIAN
Keywords: EBV, PTLD, EBNA-1, TCR-like mAb, Humanized mouse
Issue Date: 19-Jul-2016
Source: TAN WEI JIAN (2016-07-19). TREATMENT AND MODELING OF EPSTEIN-BARR VIRUS POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER. ScholarBank@NUS Repository.
Abstract: Epstein-Barr virus (EBV) is the etiological agent of infectious mononucleosis and is associated with various diseases such as Burkitt’s lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorder (PTLD). In all of these diseases, the expression of Epstein-Barr virus nuclear antigen 1 (EBNA-1) is common and therefore this viral protein represents a possible therapeutic target. Previous studies have intimated that EBNA-1 auto-inhibits its presentation to the immune system via the expression of a glycine-alanine rich domain that blocks proteasomal degradation. Thus to understand the expression of EBNA-1 and to evaluate the potential of targeting this viral antigen in the context of PTLD, we examined the role of glycine-alanine repeats (GAr) in EBNA-1 protein expression and further investigated the in vivo efficacy of an in-house produced α-EBNA-1 T cell receptor-like monoclonal antibody (α-EBNA-1 TCR-like mAb) using a mouse xenograft model of PTLD. With the aim of translating our findings into studies relevant to humans, we developed and optimized an autologous humanized mouse model for future preclinical evaluations of the antibody
URI: http://scholarbank.nus.edu.sg/handle/10635/132133
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
TanWJ.pdf9.79 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

124
checked on Jan 20, 2018

Download(s)

49
checked on Jan 20, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.